Skip to main content
SpringerLink
Log in

Dalteparin cost effective for prevention of VTE in cancer

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Comparison of Low-molecular-weight heparin versus Oral anticoagulant therapy for the prevention of recurrent venous Thromboembolism in patients with cancer

  2. 2015 Canadian dollars

Reference

  • Dranitsaris G, et al. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis. ClinicoEconomics and Outcomes Research 2017: 65-73, No. 9, 10 Jan 2017. Available from: URL: https://doi.org/10.2147/CEOR.S126379

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dalteparin cost effective for prevention of VTE in cancer. PharmacoEcon Outcomes News 770, 9 (2017). https://doi.org/10.1007/s40274-017-3684-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3684-6

Search

Navigation